Shares of Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) have been given an average recommendation of “Buy” by the six ...

Timothy A. Springer, a director and ten percent owner of Tectonic Therapeutic, Inc. (NASDAQ:TECX), has significantly increased his stake in the company through recent stock purchases. According to a ...

Tectonic Therapeutic (TECX) announced that it has entered into a securities purchase agreement for a private investment in public equity ...

Tectonic Therapeutic, Inc.’s TECX share price has dipped by 40.65%, which has investors questioning if this is right time to ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a securities purchase agreement for a ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

WATERTOWN, Mass. - Tectonic Therapeutic, Inc. (NASDAQ: TECX), a biotechnology company specializing in the development of therapeutic proteins and antibodies, announced today that it has entered into a ...

Analyst David Risinger from Leerink Partners reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report) and increased the price ...

Tectonic Therapeutic, Inc. has announced a private investment in public equity (PIPE) financing expected to generate approximately $185 million in gross proceeds. Under the agreement, Tectonic ...

Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead ...